Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Avidity Biosciences stock

RNA
US05370A1088
A2P5NK

Price

42.18
Today +/-
-7.40
Today %
-16.91 %
P

Avidity Biosciences stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Avidity Biosciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Avidity Biosciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Avidity Biosciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Avidity Biosciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Avidity Biosciences Stock Price History

DateAvidity Biosciences Price
11/15/202442.18 undefined
11/14/202449.97 undefined
11/13/202454.13 undefined
11/12/202446.73 undefined
11/11/202447.12 undefined
11/8/202446.72 undefined
11/7/202447.51 undefined
11/6/202447.24 undefined
11/5/202445.09 undefined
11/4/202444.82 undefined
11/1/202441.87 undefined
10/31/202442.26 undefined
10/30/202443.22 undefined
10/29/202444.57 undefined
10/28/202445.72 undefined
10/25/202445.11 undefined
10/24/202445.15 undefined
10/23/202445.40 undefined
10/22/202447.38 undefined
10/21/202446.71 undefined

Avidity Biosciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Avidity Biosciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Avidity Biosciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Avidity Biosciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Avidity Biosciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Avidity Biosciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Avidity Biosciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Avidity Biosciences’s growth potential.

Avidity Biosciences Revenue, EBIT and net profit per share

DateAvidity Biosciences RevenueAvidity Biosciences EBITAvidity Biosciences Net Income
2029e1.47 B undefined0 undefined450.08 M undefined
2028e864.22 M undefined188.32 M undefined445.46 M undefined
2027e374.74 M undefined-163.44 M undefined-106.85 M undefined
2026e67.15 M undefined-390.75 M undefined-402.14 M undefined
2025e12.59 M undefined-371.84 M undefined-372.68 M undefined
2024e11.41 M undefined-330.82 M undefined-340.04 M undefined
20239.56 M undefined-235.6 M undefined-212.22 M undefined
20229.22 M undefined-178.91 M undefined-174 M undefined
20219.33 M undefined-118.05 M undefined-118.01 M undefined
20206.79 M undefined-44.28 M undefined-44.36 M undefined
20192.32 M undefined-17.33 M undefined-24.73 M undefined
2018380,000 undefined-10.5 M undefined-11.22 M undefined

Avidity Biosciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2018201920202021202220232024e2025e2026e2027e2028e2029e
000.010.010.010.010.010.010.070.370.861.47
--200.0050.00--22.229.09458.33458.21131.0270.14
------------
000000000000
-11-24-44-118-174-212-340-372-402-106445450
-118.1883.33168.1847.4621.8460.389.418.06-73.63-519.811.12
44.244.237.5741.4352.1673.01000000
------------
Details

Keystats

ⓘ

Revenue and Growth

The Avidity Biosciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Avidity Biosciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201820192020202120222023
           
3.194.6328.1405.5610.7595.35
000001.11
000000
000000
0.21.13.55.612.214.85
3.395.7331.6411.1622.9611.31
0.70.61.915.61516.65
000000
000000
000000
000000
0600300900800596
0.71.22.216.515.817.25
496.9333.8427.6638.7628.56
           
33.1134.70000.01
0-0.040.370.570.941.07
-41.6-22.2-66.5-184.5-358.5-570.76
000-200-2,700125
000000
-8.569.3306.3381.5578.1500.76
1.61.97.714.132.68.81
0.31.73.210.714.343.51
03.83.74.9528.37
000000
2.72.80000
4.610.214.629.751.980.68
7.61.80000
000000
0.215.513.116.58.847.11
7.817.313.116.58.847.11
12.427.527.746.260.7127.79
3.996.8334427.7638.8628.56
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Avidity Biosciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Avidity Biosciences's financial health and stability.

Assets

Avidity Biosciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Avidity Biosciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Avidity Biosciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Avidity Biosciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201820192020202120222023
-11-24-44-118-174-212
000012
000000
01925964
088345365
000000
000000
-92-37-94-136-119
00-1-3-2-4
00-7-82-189-130
00-6-78-187-125
000000
416-4000
07230018734662
58927217634693
00-24-11031
000000
-491227-119-155
-9.712.25-38.21-98.55-139.09-123.29
000000

Avidity Biosciences stock margins

The Avidity Biosciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Avidity Biosciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Avidity Biosciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Avidity Biosciences's sales revenue. A higher gross margin percentage indicates that the Avidity Biosciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Avidity Biosciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Avidity Biosciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Avidity Biosciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Avidity Biosciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Avidity Biosciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Avidity Biosciences Margin History

Avidity Biosciences Gross marginAvidity Biosciences Profit marginAvidity Biosciences EBIT marginAvidity Biosciences Profit margin
2029e0 %0 %30.62 %
2028e0 %21.79 %51.55 %
2027e0 %-43.62 %-28.51 %
2026e0 %-581.88 %-598.84 %
2025e0 %-2,953.65 %-2,960.39 %
2024e0 %-2,899.9 %-2,980.7 %
20230 %-2,464.41 %-2,219.87 %
20220 %-1,940.46 %-1,887.2 %
20210 %-1,265.27 %-1,264.84 %
20200 %-652.14 %-653.31 %
20190 %-746.98 %-1,065.95 %
20180 %-2,763.16 %-2,952.63 %

Avidity Biosciences Stock Sales Revenue, EBIT, Earnings per Share

The Avidity Biosciences earnings per share therefore indicates how much revenue Avidity Biosciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Avidity Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Avidity Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Avidity Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Avidity Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Avidity Biosciences Revenue, EBIT and net profit per share

DateAvidity Biosciences Sales per ShareAvidity Biosciences EBIT per shareAvidity Biosciences Earnings per Share
2029e12.32 undefined0 undefined3.77 undefined
2028e7.24 undefined0 undefined3.73 undefined
2027e3.14 undefined0 undefined-0.9 undefined
2026e0.56 undefined0 undefined-3.37 undefined
2025e0.11 undefined0 undefined-3.12 undefined
2024e0.1 undefined0 undefined-2.85 undefined
20230.13 undefined-3.23 undefined-2.91 undefined
20220.18 undefined-3.43 undefined-3.34 undefined
20210.23 undefined-2.85 undefined-2.85 undefined
20200.18 undefined-1.18 undefined-1.18 undefined
20190.05 undefined-0.39 undefined-0.56 undefined
20180.01 undefined-0.24 undefined-0.25 undefined

Avidity Biosciences business model

Avidity Biosciences Inc is a biotechnology company specializing in the development of therapies for serious diseases. The company was founded in 2012 and is headquartered in San Diego, California. Avidity Biosciences works with a unique approach, using synthetic nucleic acids (oligonucleotides) that specifically bind to target molecules in the body to achieve a therapeutic effect. The business model of Avidity Biosciences is based on licensing its technology platform to partner companies. The company has already formed partnerships with several major pharmaceutical companies such as Eli Lilly, Takeda, and Astellas. These partnerships allow Avidity Biosciences to further develop and market its technology. Avidity Biosciences has several divisions: Targeted RNA-Based Therapeutics, Antibody-Oligonucleotide Conjugates, and Nucleic Acid-Based Gene Therapy. The first division focuses on developing therapies using synthetic nucleic acids that specifically bind to disease-causing target molecules and deactivate or destroy them. The second division uses antibodies to bind oligonucleotides to the target molecule and achieve a therapeutic effect. The third division develops nucleic acids for gene therapy to repair or replace genes responsible for causing a disease. An example of a product developed by Avidity Biosciences is the drug AOC 1001. This drug is an antibody-oligonucleotide conjugate used for the treatment of cancer. It works by specifically binding to the target molecule and reducing the activity of disease-causing genes. Overall, Avidity Biosciences has an innovative business model and a wide range of technologies and products that can be used to treat various diseases. Thanks to collaborations with renowned pharmaceutical companies, the company can continuously develop its technology and market its products on a global scale. Avidity Biosciences is one of the most popular companies on Eulerpool.com.

Avidity Biosciences SWOT Analysis

Strengths

Avidity Biosciences Inc possesses several strengths that contribute to its success: - Strong focus on developing and commercializing innovative biopharmaceutical products. - Proprietary technology platform allows for efficient drug targeting and delivery. - Strong portfolio of intellectual property rights protecting its products and technologies. - Strategic partnerships with reputable pharmaceutical companies, enhancing R&D capabilities.

Weaknesses

Despite its strengths, Avidity Biosciences Inc faces certain weaknesses that may hinder its growth: - Relatively small size and limited financial resources compared to larger competitors. - Dependency on successful clinical trials and regulatory approvals for new products. - Limited market presence, which may impact brand recognition and business development opportunities.

Opportunities

Avidity Biosciences Inc can leverage the following opportunities to expand its business: - Increasing demand for advanced biopharmaceuticals to treat various diseases. - Collaborative research and licensing agreements with other biotechnology companies. - Emerging markets offering untapped potential for product adoption and market expansion. - Acquisition or partnership opportunities with complementary companies to enhance product portfolio.

Threats

The following threats may pose challenges to Avidity Biosciences Inc's growth and profitability: - Intense competition from larger pharmaceutical and biotechnology companies in the industry. - Stringent regulatory requirements and potential delays in product approvals. - Rapidly evolving technological landscape increasing the pace of innovation and reducing product lifecycle. - Economic and political fluctuations impacting healthcare funding and industry dynamics.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Avidity Biosciences Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Avidity Biosciences historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Avidity Biosciences shares outstanding

The number of shares was Avidity Biosciences in 2023 — This indicates how many shares 73.012 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Avidity Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Avidity Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Avidity Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Avidity Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Avidity Biosciences.

Avidity Biosciences latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.72 -0.65  (9.53 %)2024 Q3
6/30/2024-0.8 -0.65  (18.67 %)2024 Q2
3/31/2024-0.78 -0.79  (-0.83 %)2024 Q1
12/31/2023-0.67 -0.79  (-18.51 %)2023 Q4
9/30/2023-0.78 -0.71  (8.47 %)2023 Q3
6/30/2023-0.81 -0.66  (18.2 %)2023 Q2
3/31/2023-0.86 -0.74  (13.76 %)2023 Q1
12/31/2022-0.9 -0.88  (1.83 %)2022 Q4
9/30/2022-0.94 -0.82  (12.91 %)2022 Q3
6/30/2022-0.76 -0.92  (-21.1 %)2022 Q2
1
2

Eulerpool ESG Scorecard© for the Avidity Biosciences stock

Eulerpool World ESG Rating (EESG©)

15/ 100

🌱 Environment

4

👫 Social

24

🏛️ Governance

16

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Avidity Biosciences shareholders

%
Name
Stocks
Change
Date
13.09729 % Fidelity Management & Research Company LLC15,626,3782,054,1426/30/2024
9.04989 % T. Rowe Price Associates, Inc.10,797,4213,502,0396/30/2024
6.94231 % RTW Investments L.P.8,282,870-523,9688/22/2024
5.98499 % BlackRock Institutional Trust Company, N.A.7,140,6921,669,7136/30/2024
5.45218 % Avoro Capital Advisors LLC6,505,000680,0006/30/2024
4.96703 % The Vanguard Group, Inc.5,926,1692,096,1746/30/2024
4.52637 % RA Capital Management, LP5,400,408504,4496/30/2024
4.29897 % TD Cowen (Research)5,129,103-500,0006/30/2024
4.25388 % Bristol Myers Squibb5,075,3045,075,30411/27/2023
3.18668 % Wellington Management Company, LLP3,802,0262,573,0286/30/2024
1
2
3
4
5
...
10

Avidity Biosciences Executives and Management Board

Ms. Sarah Boyce(51)
Avidity Biosciences President, Chief Executive Officer, Director (since 2019)
Compensation 5.37 M
Ms. Teresa Mccarthy(59)
Avidity Biosciences Chief Human Resource Officer
Compensation 2.27 M
Dr. W. Michael Flanagan(61)
Avidity Biosciences Chief Scientific and Technical Officer
Compensation 2.07 M
Mr. Michael Maclean(57)
Avidity Biosciences Chief Financial and Chief Business Officer
Compensation 2.04 M
Dr. Arthur Levin(69)
Avidity Biosciences Distinguished Scientist and Strategic Leader, Director (since 2014)
Compensation 1.88 M
1
2
3

Avidity Biosciences Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Eli Lilly Stock
Eli Lilly
SupplierCustomer-0,040,02-0,01-0,12-0,47-0,77
Bristol-Myers Squibb Stock
Bristol-Myers Squibb
SupplierCustomer-0,14-0,43-0,33-0,63-0,66-0,64
1

Most common questions regarding Avidity Biosciences

What values and corporate philosophy does Avidity Biosciences represent?

Avidity Biosciences Inc is committed to advancing and transforming the lives of patients through innovative RNA-based therapies. The company's corporate philosophy revolves around pioneering targeted therapies that harness the potential of antibody-oligonucleotide conjugates (AOCs) to selectively deliver medicines. By using Avidity's technology platform, AOCs aim to address complex diseases with high unmet medical needs. Avidity Biosciences Inc firmly believes in collaboration, scientific excellence, and patient-centricity, ensuring a relentless pursuit of groundbreaking solutions. Through their dedication to scientific innovation and patient-focused approach, Avidity Biosciences Inc aims to make a significant impact in improving healthcare outcomes.

In which countries and regions is Avidity Biosciences primarily present?

Avidity Biosciences Inc primarily operates in the United States.

What significant milestones has the company Avidity Biosciences achieved?

Avidity Biosciences Inc has achieved significant milestones since its inception. The company has successfully developed and maintained strategic collaborations with leading pharmaceutical companies, advancing its RNA-based therapeutics platform. Avidity Biosciences Inc also raised substantial funds through successful financing rounds, allowing for the expansion of its research and development efforts. In addition, the company has made remarkable progress in optimizing its AOC (Avidity Optimized Conjugate) technology, unlocking the potential for targeted delivery of therapeutic payloads. Avidity Biosciences Inc's dedication to innovation and collaboration has facilitated advancements in precision medicine, paving the way for potential breakthroughs in the treatment of various diseases.

What is the history and background of the company Avidity Biosciences?

Avidity Biosciences Inc is a biotechnology company specializing in the development of targeted RNA-based therapeutics. Founded in 2012, the company focuses on leveraging its proprietary AOC platform to design and develop potential treatments for a wide range of diseases. Avidity Biosciences Inc aims to address unmet medical needs by utilizing the power of oligonucleotide-based therapeutics, offering targeted and precise treatments. The company has established strategic collaborations and partnerships with other organizations to accelerate research and development efforts. With a commitment to innovation and scientific excellence, Avidity Biosciences Inc continues to advance its pipeline of potential therapies to improve patient outcomes.

Who are the main competitors of Avidity Biosciences in the market?

The main competitors of Avidity Biosciences Inc in the market are other biotechnology companies operating in the field of RNA therapeutics and gene silencing, such as Alnylam Pharmaceuticals, Moderna Inc., and Ionis Pharmaceuticals. These companies are also engaged in developing innovative RNA-based therapies for various diseases. However, Avidity Biosciences Inc distinguishes itself through its proprietary Affinity-Enabled Oligonucleotide (AEO) technology, which enables targeted delivery and tissue-specific accumulation of RNA therapeutics. By leveraging this unique technology, Avidity Biosciences Inc aims to offer differentiated solutions in the RNA therapeutics market, fostering potential advancements in personalized medicine and disease management.

In which industries is Avidity Biosciences primarily active?

Avidity Biosciences Inc primarily operates in the biotechnology industry. As a leading company in the field, Avidity Biosciences specializes in the development of innovative and targeted therapies using its proprietary AOC technology. By harnessing the power of antibody oligonucleotide conjugates, Avidity Biosciences aims to address unmet medical needs and revolutionize the treatment options for patients. With its extensive expertise, Avidity Biosciences is actively involved in advancing therapeutic solutions for diseases across various therapeutic areas, including rare genetic disorders, immunology, and oncology.

What is the business model of Avidity Biosciences?

Avidity Biosciences Inc is a pioneering biotechnology company specializing in the development of targeted RNA-based therapies. Their business model revolves around leveraging their proprietary platform, AOC platform, to engineer and optimize antibody-oligonucleotide conjugates. By combining the precision of antibodies with the potential of oligonucleotides, Avidity aims to create highly specific therapeutics that can effectively treat a range of diseases, including genetic disorders, cancer, and autoimmune conditions. Through innovative research and strategic partnerships, Avidity Biosciences Inc aims to revolutionize the field of precision medicine by delivering novel therapies that can transform patients' lives.

What is the P/E ratio of Avidity Biosciences 2024?

The Avidity Biosciences P/E ratio is -9.06.

What is the P/S ratio of Avidity Biosciences 2024?

The Avidity Biosciences P/S ratio is 269.95.

What is the Quality Investing of Avidity Biosciences?

The Quality Investing for Avidity Biosciences is 4/10.

What is the revenue of Avidity Biosciences 2024?

The expected Avidity Biosciences revenue is 11.41 M USD.

How high is the profit of Avidity Biosciences 2024?

The expected Avidity Biosciences profit is -340.04 M USD.

What is the business model of Avidity Biosciences

Avidity Biosciences Inc is a biotechnology company that focuses on the research and development of RNA-based therapeutics. It was founded in 2012 and is headquartered in La Jolla, California. The company's main business is the identification and development of RNA-based drugs that can precisely target disease agents and processes. It has developed an innovative technology called AOC (Antibody Oligonucleotide Conjugate), which allows antibodies to be specifically bound to specific RNA sequences. With this technology, it is possible to develop RNA-based therapeutics that target specific genes, enabling targeted and precise treatment of diseases. The company is utilizing this technology for the development of drugs against various diseases such as cancer, autoimmune diseases, and infections. Avidity Biosciences Inc has several products in the pipeline, including an RNA-based therapeutic for the treatment of breast cancer. The company is also working on the development of RNA-based therapeutics for the treatment of autoimmune diseases such as lupus and rheumatoid arthritis, as well as infections such as hepatitis B and C. Additionally, Avidity Biosciences Inc has a division that partners with other companies and institutions. It has formed partnerships with pharmaceutical companies such as Eli Lilly and AstraZeneca to jointly develop RNA-based therapeutics. The company also collaborates closely with academic institutions to develop research projects and investigate RNA-based therapeutics together. In addition, Avidity Biosciences Inc also offers services in the field of RNA research. These services include the identification of RNA sequences and the development of RNA-based therapeutics for clients and partner companies. Overall, the business model of Avidity Biosciences Inc is focused on the development of RNA-based therapeutics and partnership with other companies and institutions. The company utilizes its innovative technology to develop targeted and precise therapeutics that target specific disease processes. Through its partnerships and services, the company strengthens its position in the biotechnology industry and enables the faster and more successful market entry of RNA-based therapeutics.

What is the Avidity Biosciences dividend?

Avidity Biosciences pays a dividend of 0 USD distributed over payouts per year.

How often does Avidity Biosciences pay dividends?

The dividend cannot currently be calculated for Avidity Biosciences or the company does not pay out a dividend.

What is the Avidity Biosciences ISIN?

The ISIN of Avidity Biosciences is US05370A1088.

What is the Avidity Biosciences WKN?

The WKN of Avidity Biosciences is A2P5NK.

What is the Avidity Biosciences ticker?

The ticker of Avidity Biosciences is RNA.

How much dividend does Avidity Biosciences pay?

Over the past 12 months, Avidity Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Avidity Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Avidity Biosciences?

The current dividend yield of Avidity Biosciences is .

When does Avidity Biosciences pay dividends?

Avidity Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Avidity Biosciences?

Avidity Biosciences paid dividends every year for the past 0 years.

What is the dividend of Avidity Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Avidity Biosciences located?

Avidity Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Avidity Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Avidity Biosciences from 11/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/18/2024.

When did Avidity Biosciences pay the last dividend?

The last dividend was paid out on 11/18/2024.

What was the dividend of Avidity Biosciences in the year 2023?

In the year 2023, Avidity Biosciences distributed 0 USD as dividends.

In which currency does Avidity Biosciences pay out the dividend?

The dividends of Avidity Biosciences are distributed in USD.

All fundamentals about Avidity Biosciences

Our stock analysis for Avidity Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Avidity Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.